Our Pricing

Weight Loss Injections UK Online Pharmacy

Published on: June 03, 2026

Looking for trusted weight loss injections UK online pharmacy services? Cured Pharmacy offers genuine UK-licensed Mounjaro, Wegovy, and Saxenda with transparent upfront pricing, free clinical consultations under 3 minutes, and discreet next-day delivery across the UK.

How Weight Loss Injections Work in the UK

Weight loss injections available through UK pharmacies belong to a class of medications called GLP-1 receptor agonists, which mimic natural hormones that regulate appetite and blood sugar levels [1]. These prescription treatments work by slowing gastric emptying, reducing hunger signals to the brain, and improving insulin sensitivity — creating a physiological environment that supports sustainable weight reduction.

The most advanced option currently licensed in the UK is tirzepatide (Mounjaro), which uniquely targets both GLP-1 and GIP receptors. In the SURMOUNT-1 trial, patients achieved an average weight reduction of 20.9% over 72 weeks on the 15mg dose — the highest efficacy recorded in obesity pharmacotherapy to date [1]. Semaglutide-based treatments like Wegovy demonstrated average weight loss of 14.9% in the STEP-1 trial, whilst liraglutide (Saxenda) showed 8% average reduction in the SCALE trial [2][3].

All injectable weight loss medications dispensed by UK pharmacies require a prescription following clinical assessment by a UK-registered prescriber. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every patient receives appropriate medical oversight before treatment commences.

Mounjaro Weight Loss Injections: The UK's Most Effective Option

Mounjaro (tirzepatide) represents the latest advancement in prescription weight management, licensed by the MHRA in 2023 for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities [1]. As the first dual GIP/GLP-1 receptor agonist available in the UK, it activates two complementary pathways that older single-mechanism treatments cannot access.

Clinical trial data shows superior outcomes compared to previous-generation treatments. The SURPASS-3 head-to-head comparison demonstrated that tirzepatide produced significantly greater weight reduction than insulin degludec, with the 15mg dose achieving 22.5% average body weight loss over 72 weeks [4]. Patients typically start on a 2.5mg weekly dose, escalating gradually to minimise gastrointestinal side effects whilst optimising therapeutic response.

Mounjaro Dosing and Administration

Mounjaro is administered once weekly via subcutaneous injection using a pre-filled KwikPen device. The standard titration schedule begins at 2.5mg for four weeks, increasing to 5mg, then 7.5mg, 10mg, 12.5mg, and finally 15mg at four-week intervals, subject to tolerability and prescriber guidance [1]. Each pen contains four doses, and injection sites should be rotated between the abdomen, thigh, or upper arm to reduce injection site reactions.

Wegovy and Saxenda: Proven Semaglutide and Liraglutide Options

Wegovy contains semaglutide, a GLP-1 receptor agonist that has been extensively studied across the STEP clinical trial programme involving over 4,500 participants [2]. In STEP-1, adults without diabetes achieved an average 14.9% weight reduction over 68 weeks on the 2.4mg weekly dose, compared to 2.4% with placebo. Wegovy is administered once weekly, with dosing escalating from 0.25mg to a maintenance dose of 2.4mg over 16 weeks.

Saxenda (liraglutide) offers a daily injection alternative for patients who prefer more frequent, lower-dose administration. The SCALE Obesity and Prediabetes trial showed 8% average weight loss over 56 weeks, with 63.2% of participants achieving at least 5% weight reduction [3]. Saxenda requires daily subcutaneous injection, starting at 0.6mg and increasing weekly to a maintenance dose of 3mg.

Both medications are licensed by the MHRA for chronic weight management and require ongoing clinical monitoring. Your UK prescriber will determine which treatment aligns with your medical history, lifestyle preferences, and weight management goals during your confidential online consultation.

Choosing Between Weekly and Daily Injections

Weekly injections like Mounjaro and Wegovy offer convenience and may improve adherence for patients with busy schedules, whilst daily Saxenda provides more granular dose control and may suit those who prefer consistent daily routines. Clinical efficacy, tolerability profile, and cost considerations should all inform your decision, which your prescriber will discuss during assessment.

Orlistat and Oral Weight Loss Treatments Available in the UK

For patients who prefer non-injectable options, orlistat remains the only oral prescription weight loss medication licensed in the UK. Available as 120mg prescription-strength capsules (Xenical, Orlistat) or 60mg over-the-counter formulations (Alli, Orlos), orlistat works by inhibiting pancreatic lipase enzymes, reducing dietary fat absorption by approximately 30% [5].

Clinical trials demonstrate that orlistat combined with a reduced-calorie diet produces average weight loss of 5-10% over 12 months, with greatest efficacy in patients who adhere to a low-fat eating plan [5]. Unlike GLP-1 treatments that suppress appetite centrally, orlistat requires active dietary modification to minimise gastrointestinal side effects such as steatorrhoea and faecal urgency.

Wegovy Oral Tablets (semaglutide pill) represent an emerging option currently available for pre-order through UK pharmacies. This formulation delivers the same active ingredient as injectable Wegovy but via daily oral administration, offering an alternative for patients with needle aversion whilst maintaining the appetite-suppressing benefits of GLP-1 receptor agonism.

Weight Loss Injections UK: Safety, Side Effects, and Monitoring

All GLP-1 receptor agonists carry a consistent side effect profile, with gastrointestinal symptoms being most common. In clinical trials, nausea affected 20-44% of participants, typically peaking during dose escalation and diminishing over 4-8 weeks [1][2]. Other frequent effects include diarrhoea, constipation, vomiting, and abdominal discomfort, which can be minimised through gradual titration and dietary adjustments.

Rare but serious adverse events include pancreatitis, gallbladder disease, and hypoglycaemia (particularly in patients taking concurrent diabetes medications). The MHRA requires ongoing pharmacovigilance, and patients should report persistent abdominal pain, jaundice, or severe nausea to their prescriber immediately [6]. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and pregnancy.

UK prescribers conduct baseline assessments including BMI calculation, medical history review, and evaluation of weight-related comorbidities before initiating treatment. Ongoing monitoring typically includes monthly check-ins during the first three months, with treatment continuation dependent on achieving at least 5% weight loss after 12 weeks at the therapeutic dose, in line with NICE guidance [7].

Who Can Access Weight Loss Injections in the UK

NICE and MHRA licensing criteria specify that prescription weight loss injections are appropriate for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [7]. Your UK prescriber will verify eligibility during your clinical assessment, which takes under 3 minutes to complete online.

Why Choose Cured Pharmacy for Weight Loss Injections UK

As a GPhC-registered online pharmacy (registration number 9012511), Cured Pharmacy dispenses only genuine UK-licensed medications sourced through regulated supply chains. Every prescription is clinically reviewed by our UK-registered prescribers, with superintendent pharmacist Tarun Kumar (GPhC 2233073) providing clinical oversight across all weight management services.

We guarantee transparent upfront pricing — you'll see exact costs before completing your consultation, with no hidden fees or subscription traps. Our prices are amongst the most competitive in the UK market, with Mounjaro available from £135.00, Wegovy from £135.00, and Saxenda from £135.00. All orders are dispatched in 100% discreet packaging via next-day delivery, arriving in plain, unmarked parcels.

Our online consultation takes under 3 minutes and is reviewed by UK prescribers typically within 24 hours. If your treatment is approved, your medication is dispensed immediately and dispatched from our UK pharmacy. Should you have questions during treatment, our clinical team is available via phone on (+44) 116 4646009 or through your secure patient portal.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-218. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & SCALE Obesity and Prediabetes NN8022-1839 Study Group. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
4. Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., ... & SURPASS-3 Investigators. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet, 398(10300), 583-598. https://doi.org/10.1016/S0140-6736(21)01443-4 [accessed 13 August 2026]
5. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155-161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
6. Medicines and Healthcare products Regulatory Agency. (2023). GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued. Drug Safety Update, 16(9). https://www.gov.uk/drug-safety-update [accessed 13 August 2026]
7. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE Clinical Guideline. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to lifestyle modifications alongside pharmacotherapy.